Most of our patients begin to see initial reductions in symptoms within 3–6 months of treatment, with long-term reduction in symptoms and independence from medication after 1.5–2 years of treatment at our dosages.
Studies at lower dosages show that those who complete 3 years of treatment often result in life-long remission of their allergies.
Biscuit Health is actively exploring ways to reduce treatment time to make allergy care more accessible and affordable for Canadians. We plan on publishing our own studies of how we are able to go above and beyond current industry success rates by taking a patient-centric and data-backed approach.
In the meantime, please see the below studies for reference on length of treatment.
Articles/studies for reference
Study | Summary | Key findings |
SLIT results in a 32% reduction in combined symptom & medication scores after 3–6 months of treatment. | Primary efficacy results demonstrated a significant (P < .0001) and clinically relevant (32%) reduction in the combined symptom and medication score compared with placebo after 3 to 6 months of SLIT. | |
Symptom reduction can be seen as early as 14 weeks of SLIT treatment. | SLIT with a mixture of D.f. and D.p. extract is an effective and safe treatment for patients with house dust mite-induced AR. Its onset of action can be observed as early as 14 weeks after treatment. | |
4 years of immunotherapy at 3x per week totalling 390µg cumulative antigen annually can result in permanent relief. Note: Biscuit delivers 7x per week totalling ~900µg annually to reduce treatment time to ~1.5–2 years. | A 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination. | |
3 years of immunotherapy resulted in long-lasting effects under 6,200 BAU per day. Note: Biscuit delivers 10,000 BAU per day to reduce treatment time to ~1.5–2 years. | The mean rhinoconjunctivitis daily symptom score was reduced by 25–36% in the active group. Efficacy was supported by long-lasting significant effects on the allergen-specific antibody response. |